Zydus Lifesciences gains on incorporating wholly owned subsidiary in UAE
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 910.90, up by 6.10 points or 0.67% from its previous closing of Rs. 904.80 on the BSE.
The scrip opened at Rs. 892.60 and has touched a high and low of Rs. 911.75 and Rs. 892.60 respectively. So far 17555 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 916.60 on 23-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023.
Last one week high and low of the scrip stood at Rs. 916.60 and Rs. 888.55 respectively. The current market cap of the company is Rs. 91705.69 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.03% and 6.99% respectively.
Zydus Lifesciences has incorporated a wholly owned subsidiary company (WOS) in the name of Zydus Lifesciences Global FZE in Jebel Ali Free Zone (ZAFZA), United Arab Emirates (UAE). The company has incorporated WOS on February 20, 2024.
Earlier, the company had received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 1 mg (USRLD: Dexamethasone Tablets).
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
